Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Abatacept.

Edward M Vital1, Paul Emery

  • 1Academic Unit of Musculoskeletal Disease, University of Leeds, Chapel Allerton Hospital, Leeds, UK.

Drugs of Today (Barcelona, Spain : 1998)
|March 17, 2006
PubMed
Summary
This summary is machine-generated.

New therapies like costimulation blockers offer hope for rheumatoid arthritis patients unresponsive to other treatments. Abatacept demonstrates safety and efficacy, targeting T-cell function in autoimmune diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Executive Summary: The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus.

Rheumatology (Oxford, England)·2026
Same author

The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus.

Rheumatology (Oxford, England)·2026
Same author

Long-Term Anifrolumab Treatment Normalizes Hematologic Parameters and Several Serologic Markers in Patients With Systemic Lupus Erythematosus.

ACR open rheumatology·2026
Same author

Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026
Same author

Real-world experience of anifrolumab treatment in patients with moderate-to-severe SLE: a retrospective study of patients in early access programmes.

Lupus science & medicine·2026
Same author

Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus.

The New England journal of medicine·2026
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) involves chronic inflammation, with tumor necrosis factor-alpha (TNF-α) inhibitors improving outcomes for some.
  • A significant patient subset lacks adequate response or tolerates TNF-α inhibitors poorly, necessitating alternative treatments.
  • T-cell activation is critical in RA pathogenesis, indicating T-cell-targeted therapies as a promising avenue.

Purpose of the Study:

  • To introduce abatacept, a novel costimulation blocker, as a targeted therapy for autoimmune diseases like RA.
  • To review the demonstrated safety and efficacy of abatacept in rheumatoid arthritis patients.
  • To highlight ongoing research into abatacept and other costimulation blockers for RA and other autoimmune conditions.

Main Methods:

Related Experiment Videos

  • Clinical trials evaluating abatacept's safety and efficacy in rheumatoid arthritis.
  • Mechanism of action studies focusing on T-cell costimulation blockade.
  • Comparative analysis of treatment outcomes between abatacept and existing RA therapies.

Main Results:

  • Abatacept has shown a favorable safety profile in rheumatoid arthritis.
  • Abatacept demonstrated significant efficacy in controlling inflammation and improving patient outcomes in RA.
  • Ongoing trials are exploring abatacept's potential in other autoimmune diseases.

Conclusions:

  • Abatacept represents a new class of targeted immunomodulatory drugs for rheumatoid arthritis.
  • Costimulation blockers offer a valuable therapeutic option for RA patients who do not respond to or tolerate TNF-α inhibitors.
  • Further investigation into abatacept and similar agents is warranted for broader application in autoimmune diseases.